Skip to main content

Advertisement

Log in

Detection of occult HER2 mRNA-positive tumor cells in the peripheral blood of patients with operable breast cancer: evaluation of their prognostic relevance

  • Preclinical Study
  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

An Erratum to this article was published on 21 January 2009

Abstract

To evaluate whether HER2 mRNA could be used as a marker of circulating tumor cells (CTCs) in women with operable breast cancer. A nested RT-PCR assay was developed and used for the detection of HER2 mRNA-positive CTCs. Blood from 216 women with early breast cancer obtained before adjuvant treatment was tested for HER2 mRNA-positive cells to assess their prognostic value. Nested RT-PCR for HER2 mRNA showed high sensitivity whereas no HER2 mRNA-positive cells could be identified in the blood of healthy donors. HER2 mRNA-positive CTCs were detected in 53 (24.5%) of 216 patients and HER2 mRNA detection was associated with reduced disease-free survival (DFS; P < 0.0001) and overall survival (OS; P = 0.004). In multivariate analysis, detection of HER2 mRNA-positive CTCs emerged as independent prognostic factor for DFS (P = 0.0001) and OS (P = 0.003). HER2 mRNA could be a valuable prognostic marker for the detection of CTCs in early breast cancer patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Pantel K, Cote RJ, Fodstad O (1999) Detection and clinical importance of micrometastatic disease. J Natl Cancer Inst 91:1113–1124. doi:10.1093/jnci/91.13.1113

    Article  PubMed  CAS  Google Scholar 

  2. Braun S, Pantel K, Muller P et al (2000) Cytokeratin-positive cells in the bone marrow and survival of patients with stage I, II or III breast cancer. N Engl J Med 342:525–533. doi:10.1056/NEJM200002243420801

    Article  PubMed  CAS  Google Scholar 

  3. Diel IJ, Kaufmann M, Costa SD et al (1996) Micrometastatic breast cancer cells in bone marrow at primary surgery: Prognostic value in comparison with nodal status. J Natl Cancer Inst 88:1652–1658. doi:10.1093/jnci/88.22.1652

    Article  PubMed  CAS  Google Scholar 

  4. Mansi JL, Easton D, Berger U et al (1991) Bone marrow micrometastases in primary breast cancer: prognostic significance after 6 years’ follow-up. Eur J Cancer 27:1552–1555

    Article  PubMed  CAS  Google Scholar 

  5. Stathopoulou A, Vlachonikolis I, Mavroudis D et al (2002) Molecular detection of cytokeratin–19-positive cells in the peripheral blood of patients with operable breast cancer: Evaluation of their prognostic significance. J Clin Oncol 20:3404–3412. doi:10.1200/JCO.2002.08.135

    Article  PubMed  CAS  Google Scholar 

  6. Xenidis N, Perraki M, Kafousi M et al (2006) Predictive and prognostic value of peripheral blood cytokeratic-19 mRNA positive cells detected by real time PCR in node-negative breast cancer patients. J Clin Oncol 24:3756–3762. doi:10.1200/JCO.2005.04.5948

    Article  PubMed  CAS  Google Scholar 

  7. Braun S, Vogl FD, Naume B et al (2005) A pooled analysis of bone marrow micrometastasis in breast cancer. N Engl J Med 353:793–802. doi:10.1056/NEJMoa050434

    Article  PubMed  CAS  Google Scholar 

  8. Zach O, Kasparu H, Krieger O et al (1999) Detection of circulating mammary carcinoma cells in the peripheral blood of breast cancer patients via a nested reverse transcriptase polymerase chain reaction assay for mammaglobin mRNA. J Clin Oncol 17:2015–2019

    PubMed  CAS  Google Scholar 

  9. Luppi M, Morselli M, Bandieri E et al (1996) Sensitive detection of circulating breast cancer cells by reverse-transcriptase polymerase chain reaction of maspin gene. Ann Oncol 7:619–624

    PubMed  CAS  Google Scholar 

  10. Gerhard M, Juhl H, Kalthoff H et al (1994) Specific detection of carcinoembryonic antigen-expressing tumor cells in bone marrow aspirates by polymerase chain reaction. J Clin Oncol 12:725–729

    PubMed  CAS  Google Scholar 

  11. Stathopoulou A, Mavroudis D, Perraki M et al (2003) Molecular detection of cancer cells in the peripheral blood of patients with breast cancer: Comparison of CK-19, CEA and maspin as detection markers. Anticancer Res 23:1883–1890

    PubMed  CAS  Google Scholar 

  12. Brandt B, Roetger A, Heidl S et al (1998) Isolation of blood-bored epithelium-derived c-erb-B2 oncoprotein-positive clustered cells from the peripheral blood of breast cancer patients. Int J Cancer 76:824–828. doi:10.1002/(SICI)1097-0215(19980610)76:6<824::AID-IJC10>3.0.CO;2-2

    Article  PubMed  CAS  Google Scholar 

  13. Solomayer EF, Becker S, Pergolo-Becker G et al (2006) Comparison of HER2 status between primary tumor and disseminated tumor cells in primary breast cancer patients. Breast Cancer Res Treat 98:179–184. doi:10.1007/s10549-005-9147-y

    Article  PubMed  CAS  Google Scholar 

  14. Braun S, Schlimok G, Heumos I et al (2001) erbB2 overexpression on occult tumor metastatic cells in bone marrow predicts poor clinical outcome of stage I-II breast cancer patients. Cancer Res 61:1890–1892

    PubMed  CAS  Google Scholar 

  15. Schechter AL, Stern DF, Vaidyanathan L et al (1984) The neu oncogene: an erb-B-related gene encoding a 185000-Mr tumour antigen. Nature 312:513–516. doi:10.1038/312513a0

    Article  PubMed  CAS  Google Scholar 

  16. Slamon DJ, Clark GM, Wong SG et al (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER2/neu oncogene. Science 235:177–182. doi:10.1126/science.3798106

    Article  PubMed  CAS  Google Scholar 

  17. Slamon DJ, Godolphin W, Jones LA et al (1989) Studies of the HER-2/neu proto oncogene in human breast cancer and ovarian cancer. Science 244:707–712. doi:10.1126/science.2470152

    Article  PubMed  CAS  Google Scholar 

  18. Toikkanen S, Helin H, Isola J et al (1992) Prognostic significance of HER-2 oncoprotein expression in breast cancer: a 30-year follow-up. J Clin Oncol 10:1044–1048

    PubMed  CAS  Google Scholar 

  19. Wulfing P, Brochard J, Buerger H et al (2006) HER 2 positive circulating tumor cells indicate poor clinical outcome in stage I to III breast cancer patients. Clin Cancer Res 12:1715–1720. doi:10.1158/1078-0432.CCR-05-2087

    Article  PubMed  Google Scholar 

  20. Wasserman L, Dreilinger A, Easter D et al (1999) A seminested RT-PCR assay for HER2/neu: initial validation of a new method for the detection of disseminated breast cancer cells. Mol Diagn 4:21–28. doi:10.1016/S1084-8592(99)80046-0

    Article  PubMed  CAS  Google Scholar 

  21. Thomas DG, Giordano TJ, Sanders D et al (2002) Absence of Her2/neu gene expression in osteosarcoma and skeletal Ewing’s sarcoma. Clin Cancer Res 8:788–793

    PubMed  CAS  Google Scholar 

  22. Bozionellou V, Mavroudis D, Perraki M et al (2004) Trastuzumab administration can effectively target chemotherapy-resistant cytokeratin-19 messenger RNA-positive tumor cells in the peripheral blood and bone marrow of patients with breast cancer. Clin Cancer Res 10:8185–8194. doi:10.1158/1078-0432.CCR-03-0094

    Article  PubMed  CAS  Google Scholar 

  23. Armitage P, Berry G (1994) Statistical methods in medical research, 3rd edn. Blackwell Scientific, Oxford

    Google Scholar 

  24. Stathopoulou A, Gizi A, Perraki M et al (2003) Real-time quantification of CK-19 mRNA positive cells in peripheral blood of breast cancer patients using the LightCycler system. Clin Cancer Res 9:5145–5151

    PubMed  CAS  Google Scholar 

  25. Muller P, Weckermann D, Riethmuller G et al (1996) Detection of genetic alterations in micrometastatic cells in bone marrow of cancer patients with fluorescence in situ hybridization. Cancer Genet Cytogenet 88:8–16. doi:10.1016/0165-4608(95)00189-1

    Article  PubMed  CAS  Google Scholar 

  26. Meng S, Tripathy D, Shete S et al (2004) HER2 gene amplification can be aquired as breast cancer progresses. Proc Natl Acad Sci USA 101:9393–9398. doi:10.1073/pnas.0402993101

    Article  PubMed  CAS  Google Scholar 

  27. Zidan J, Dashkovsky I, Stayerman C et al (2005) Comparison of HER-2 overexpression in primary breast cancer and metastatic sites and its effect on biological targeting therapy of metastatic disease. Br J Cancer 93:552–556. doi:10.1038/sj.bjc.6602738

    Article  PubMed  CAS  Google Scholar 

  28. Apostolaki S, Perraki M, Pallis A et al (2007) Circulating HER2 mRNA-positive cells in the peripheral blood of patients with stage I and II breast cancer after the administration of adjuvant chemotherapy: evaluation of their clinical relevance. Ann Oncol 18:851–858. doi:10.1093/annonc/mdl502

    Article  PubMed  CAS  Google Scholar 

  29. Braun S, Kentenich C, Janni W et al (2000) Lack of effect of adjuvant chemotherapy on the elimination of single dormant tumor cells in the bone marrow of high-risk breast cancer patients. J Clin Oncol 18:80–86

    PubMed  CAS  Google Scholar 

  30. Xenidis N, Vlachonikolis I, Mavroudis D et al (2003) Peripheral blood circulating cytokeratin-19 mRNA-positive cells after the completion of adjuvant chemotherapy in patients with operable breast cancer. Ann Oncol 14:849–855. doi:10.1093/annonc/mdg259

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

Supported in part by grants from the Cretan Association for Biomedical Research (CABR), Pfizer Hellas and co-funded by the European Social Fund and National Resources.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Dimitris Mavroudis.

Additional information

An erratum to this article can be found at http://dx.doi.org/10.1007/s10549-008-0298-5

Rights and permissions

Reprints and permissions

About this article

Cite this article

Apostolaki, S., Perraki, M., Kallergi, G. et al. Detection of occult HER2 mRNA-positive tumor cells in the peripheral blood of patients with operable breast cancer: evaluation of their prognostic relevance. Breast Cancer Res Treat 117, 525–534 (2009). https://doi.org/10.1007/s10549-008-0239-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10549-008-0239-3

Keywords

Navigation